Printed from Voxsanity (voxsanity.com.au) — NCT06012240 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You must be an adult younger than 64 years old at the time of your first study visit (in some countries outside the US and EU, teenagers aged 12 and older may also be able to join certain parts of the study — check with the trial site).
You must have been diagnosed with severe alopecia areata (a condition causing significant hair loss), with at least 50% of your scalp hair lost, confirmed at two early study appointments.
Your scalp hair must not have started growing back on its own in the past 6 months.
Your current episode of alopecia areata must have started less than 8 years ago.
Who may not be able to join:
You would not be eligible if your alopecia areata is mainly the "diffuse" type, where hair loss is spread evenly across the scalp rather than in patches.
You would not be eligible if you have another type of hair loss condition (such as common male or female pattern baldness at a certain stage, traction alopecia, or several other specific scalp conditions) that could affect how the trial results are measured.
You would not be eligible if you have another inflammatory condition affecting your scalp, eyebrows, or eyelashes (such as scalp psoriasis, seborrheic dermatitis, eczema, or a fungal scalp infection) that could interfere with the study results, as decided by the study doctor.
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Veracity Clinical Research /ID# 258566, Woolloongabba, Queensland
Skin Health Institute Inc /ID# 258570, Carlton, Victoria
Sinclair Dermatology - Melbourne /ID# 258565, East Melbourne, Victoria
The Royal Melbourne Hospital /ID# 258770, Parkville, Victoria
Fremantle Dermatology /ID# 260207, Fremantle, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06012240
Sponsor: AbbVie
Phase: Phase 3
Status: Recruiting
Condition: Alopecia Areata
Trial contact: 844-663-3742
More information: https://clinicaltrials.gov/study/NCT06012240
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You must be an adult younger than 64 years old at the time of your first study visit (in some countries outside the US and EU, teenagers aged 12 and older may also be able to join certain parts of the study — check with the trial site).
You must have been diagnosed with severe alopecia areata (a condition causing significant hair loss), with at least 50% of your scalp hair lost, confirmed at two early study appointments.
Your scalp hair must not have started growing back on its own in the past 6 months.
Your current episode of alopecia areata must have started less than 8 years ago.
Who may not be able to join:
You would not be eligible if your alopecia areata is mainly the "diffuse" type, where hair loss is spread evenly across the scalp rather than in patches.
You would not be eligible if you have another type of hair loss condition (such as common male or female pattern baldness at a certain stage, traction alopecia, or several other specific scalp conditions) that could affect how the trial results are measured.
You would not be eligible if you have another inflammatory condition affecting your scalp, eyebrows, or eyelashes (such as scalp psoriasis, seborrheic dermatitis, eczema, or a fungal scalp infection) that could interfere with the study results, as decided by the study doctor.
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇭🇷 Croatia
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇿 New Zealand
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇸🇰 Slovakia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20; Number of Participants with Adverse Events (AEs)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.